The market’s noisy again, but one quietly consistent name is proving that fundamentals still pay better than hype. 

While everyone’s chasing the next breakout, this steady performer’s been doing something rarer: compounding quietly, quarter after quarter, until the numbers became too good to ignore.

Topgolf revolutionized golf by turning it into a social, tech-driven game for anyone. And they’ve made billions in annual revenue doing it. Surf Lakes is applying that same model to surfing. Their patented tech creates 2,000 ocean-quality rides per hour, anywhere in the world, across all skill levels.

Surf tourism is a $65B global industry, yet fewer than 1% of people live near real waves. Licenses sold across the U.S. and Australia, with plans for a first commercial park in the works.

3x world champ Tom Curren and surf icon Mark Occhilupo have joined as ambassadors and shareholders. Even actor Chris Hemsworth has praised Surf Lakes.

You have until October 30th at 11:59 PM PT to invest in Surf Lakes.

Invest In Surf Lakes

_{This is a paid advertisement for Surf Lakes’ Regulation CF offering. Please read the offering circular at https://invest.surflakes.com}

Don’t Let These Undervalued Stocks Slip Through Your Fingers!

We now send our favorite value picks via text, too, so you’ll get the same actionable news without having to open your inbox.

👉 Click here to get stock picks by text and uncover the best value opportunities!

Education and Training

Adtalem Global Education (NYSE: ATGE) has been making headlines for all the right reasons.

The stock’s been on a roll, driven by solid earnings and a steady stream of investor confidence that just won’t quit.

The company’s latest results reminded the market that education isn’t just about classrooms and tuition checks; it’s a serious business when done right.

Adtalem’s focus on professional and medical education has built it a reputation for consistency and credibility.

Its strategy isn’t flashy, but it works.

Investors like what they’re seeing: stable demand, operational discipline, and leadership that seems to know exactly what test they’re studying for.

The recent share price climb feels less like luck and more like the outcome of smart planning.

Of course, valuation chatter always lingers, but that’s just noise compared to the company’s bigger story of steady growth, solid margins, and a knack for staying focused.

Adtalem is proving that education can be profitable without cutting corners.

In a market full of hype-driven moves, this stock stands out for the right reasons.

It’s one of those rare education names that doesn’t just deliver lessons; it hands one back to the market on how to perform under pressure.

Biotech

Grifols (NASDAQ: GRFS) is back in the spotlight as investors revisit the Spanish plasma specialist for its value appeal.

The buzz comes from analysts flagging the stock’s attractive valuation metrics, a refreshing twist in a market dominated by pricey growth names.

With fundamentals firming up and earnings momentum building, the company’s finally earning our attention — we’ll always take real cash flow over hype and a strong balance sheet over wishful thinking.

Grifols has carved out a durable niche in plasma therapies and diagnostics, and its operating cash flow growth now reflects real execution, not luck.

Margins are firming as cost controls kick in, and debt reduction continues to improve flexibility.

The market still prices it like a turnaround story, but the numbers say otherwise.

At roughly 9x forward earnings and a price-to-sales ratio under 1, the valuation looks misaligned with improving fundamentals.

The company’s plasma collections are back above pre-pandemic levels, production costs are easing, and free cash flow has flipped positive.

That combination sets the stage for an earnings re-rating if sentiment catches up.

This isn’t a speculative swing; it’s a value setup grounded in operational recovery and hard cash.

Medical Technology and Devices

Stevanato Group (NYSE: STVN) is back in focus as we gear up for its upcoming earnings report in early November.

The Italian packaging and medical device maker has been drawing attention for steady growth, tight execution, and a stock that refuses to buckle in a volatile market.

Trading in the mid-20s with analyst targets near 29, we are really just looking for confirmation that the next earnings print can extend the momentum and justify a re-rate built on consistency rather than hype.

The story here isn’t just about glass vials and precision devices, though; it’s about steady execution in a sector where reliability is gold.

Stevanato’s calm trading rhythm and consistent growth have earned it a loyal base of long-term holders who appreciate predictable results more than flashy surprises.

The company’s expanding global footprint and strong partnerships in pharma manufacturing have also helped it build quite a credibility in a high-stakes space.

While the dividend yield is modest, the company’s focus on innovation and contract wins keeps the long-term outlook intact.

As earnings season approaches, we are hoping for a clear signal that demand for healthcare packaging remains firm.

For now, Stevanato looks like one of those quiet operators preparing to make a little more noise.

Cinemark Holdings (NYSE: CNK) is back in focus this week as investors take another look at the theater chain’s blockbuster recovery story.

After years of rebuilding, the company’s return to profitability has turned into a solid long-term win for shareholders, who’ve enjoyed strong total returns fueled by both price gains and dividends.

The recent momentum suggests that the comeback still has legs, as movie attendance and revenue trends continue to improve.

For value-focused investors, Cinemark now stands as one of those rare post-pandemic survivors that actually learned how to thrive again.

With earnings stability and shareholder rewards back in the frame, CNK’s reel of results is worth another viewing.

BJ’s Restaurants (NASDAQ: BJRI) is catching eyes this week as value investors dig in for another look.

The stock’s valuation still looks tasty, trading below industry averages while keeping its fundamentals steady.

Analysts like the setup, calling BJRI one of the stronger value plays in its space.

What’s got investors interested is the balance between affordability and dependability.

Earnings projections are holding up, margins are stable, and the market hasn’t fully priced in that resilience.

In a landscape where many names look overcooked, BJRI stands out as one of the few still serving genuine value.

Axis Capital (NYSE: AXS) is another one to look out for as we dig into a setup that looks too good to ignore.

The insurer’s mix of strong earnings revisions and solid valuation metrics has made it a name worth watching, especially as analysts lift their forecasts heading into 2025.

The stock trades at levels that make sense for anyone hunting quality at a reasonable price, and the company’s recent track record of earnings surprises adds fuel to the story.

What keeps AXS in the conversation is its balance of discipline and upside.

It’s running a tight ship, delivering profit consistency without overextending.

For long-term investors looking for sturdy value in a choppy market, Axis Capital fits the bill.

That's our coverage for today; thanks for reading! Reply to this email with feedback or any value names you'd like us to dig into.

Best Regards,
—Noah Zelvis
Undervalued Edge